These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8797480)

  • 41. Discontinuation of prolonged bromocriptine therapy in Parkinson's disease patients with uncontrolled motor oscillations.
    Giménez-Roldán S; Mateo D
    Clin Neuropharmacol; 1994 Oct; 17(5):435-44. PubMed ID: 9316693
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson's disease.
    Shiraishi M; Kamo T; Hotta M; Nemoto S; Oshima J; Sugihara H; Yasaki S; Kawakami M; Takahashi Y; Shimojo S
    J Neural Transm (Vienna); 2004 Jun; 111(6):725-32. PubMed ID: 15168219
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of parkinson's disease with bromocriptine.
    Lieberman A; Kupersmith M; Estey E; Goldstein M
    N Engl J Med; 1976 Dec; 295(25):1400-4. PubMed ID: 989885
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Cabergoline in the treatment of Parkinson's disease].
    Pastor P; Tolosa E
    Neurologia; 2003 May; 18(4):202-9. PubMed ID: 12721865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of high-dose cabergoline in Parkinson's disease.
    Odin P; Oehlwein C; Storch A; Polzer U; Werner G; Renner R; Shing M; Ludolph A; Schüler P
    Acta Neurol Scand; 2006 Jan; 113(1):18-24. PubMed ID: 16367894
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lifecorder: a new device for the long-term monitoring of motor activities for Parkinson's disease.
    Saito N; Yamamoto T; Sugiura Y; Shimizu S; Shimizu M
    Intern Med; 2004 Aug; 43(8):685-92. PubMed ID: 15468966
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
    Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B
    Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
    Pinter MM; Pogarell O; Oertel WH
    J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):436-41. PubMed ID: 10201413
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New pharmacotherapy for Parkinson's disease.
    Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
    Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
    Webster J; Piscitelli G; Polli A; Ferrari CI; Ismail I; Scanlon MF
    N Engl J Med; 1994 Oct; 331(14):904-9. PubMed ID: 7915824
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease.
    Del Dotto P; Colzi A; Musatti E; Strolin Benedetti M; Persiani S; Fariello R; Bonuccelli U
    Clin Neuropharmacol; 1997 Oct; 20(5):455-65. PubMed ID: 9331523
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Controlled study of the antiparkinsonian activity and tolerability of cabergoline.
    Hutton JT; Morris JL; Brewer MA
    Neurology; 1993 Mar; 43(3 Pt 1):613-6. PubMed ID: 8451010
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of the effects of bromocriptine and levodopa in Parkinson's disease.
    Godwin-Austen RB; Smith NJ
    J Neurol Neurosurg Psychiatry; 1977 May; 40(5):479-82. PubMed ID: 330825
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
    Fariello RG
    Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
    Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
    Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Second generation of dopamine agonists: pros and cons.
    Rabey JM
    J Neural Transm Suppl; 1995; 45():213-24. PubMed ID: 8748628
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease.
    Ramaker C; Hilten JJ
    Cochrane Database Syst Rev; 2002; (2):CD003634. PubMed ID: 12076493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.